Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.65 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753167 | 0.88 | RAB9A (0.81) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| SCHEMBL5123998 | 0.81 | POLB (0.62) | RAB9AALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL21749040 | 0.79 | SSTR4 (1.00) | SSTR1SSTR4 | |
| SCHEMBL4033699 | 0.78 | ATF4 (0.81) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| SCHEMBL19692630 | 0.78 | ATF4 (0.59) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| Hydrochloric Acid SCHEMBL19692584 | 0.77 | ATF4 (0.79) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| Hydrochloric Acid SCHEMBL19692616 | 0.77 | ATF4 (0.58) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| SCHEMBL5124087 | 0.77 | MCHR1 (0.61) | RAB9AHPGDSMN1; SMN2HTTPOLB | |
| SCHEMBL2559155 | 0.75 | HPGD (0.56) | RAB9AALDH1A1HPGDNPC1KMT2A | |
| SCHEMBL16083213 | 0.75 | NPC1 (0.78) | RAB9AALDH1A1HPGDNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| CN-1934099-A | N-piperidine derivates as CCR3 modulators | ASTRAZENECA AB (SE) | 2007-03-21 | — | — | CN | claimed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | claimed |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| CN-1934099-A | N-piperidine derivates as CCR3 modulators | ASTRAZENECA AB (SE) | 2007-03-21 | — | — | CN | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | SSTR1 3413/4885SSTR4 3249/4885RAB9A 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.